Search for a trial

SCENT
part 3. Acute effects on smellprints of chemotherapy in patients with lung cancer.

We hypothesize that chemotherapy-induced changes in exhaled metabolites in lung cancer can be detected by changes in VOC profiles (smell-prints) measured by the eNose.

A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrence

The primary aim of the study is to investigate whether it is possible to select patients by PET in a good prognosis group (i.e. low SUV) who will not benefit from adjuvant chemotherapy.

SCENT
part 2. Identification of patients with lung cancer and breast cancer.

We will test the hypothesis that smellprints can identify and classify newly presented patients prospectively into the categories of non small cell lung cancer (NSCLC) and breast cancer.

Preoperative risk estimation for onco-geriatric patients.

This study will be performed to test the predictive value of the GFI, the VES-13 and the timed “up and go” test compared to components of PACE in elderly patients of the age of 70 years and above undergoing surgery for a solid tumour.

SCENT 1. Differences in smellprints between patients with lung cancer and breast cancer.

We hypothesize that an electronic nose can discriminate the VOC pattern in exhaled breath between patients with non small cell lung cancer (NSCLC) and breast cancer.

Assessing effects of physician-patient communication

If subjects view a video a medical consultation, then viewing physician-patient commmunication will yield similar psychological and physiological responses as when that subject is taking part in that consultation.